Losartan Potassium Tablet, Film Coated
Product Images NDC 42708-151

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 42708-151). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qpharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (42708 151 30)

Label for Losartan Potassium Tablet USP, 25 mg, film-coated tablets, containing 30 tablets per container. The label shows the product name, strength, quantity, and usage instructions to take tablets at specified times. The labeler is QPharma, Inc., located in Cedar Knolls, NJ. Additional instructions include storing at controlled room temperature and keeping the container tightly closed and out of reach of children.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with primary endpoints over 60 study months for Atenolol and Losartan Potassium. The graph shows an adjusted risk reduction of 13% (p=0.021) favoring Losartan Potassium, with a lower cumulative percentage of patients reaching the endpoint compared to Atenolol.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line chart comparing the percentage of patients with fatal/non-fatal stroke over study months between Losartan Potassium and Atenolol. The graph shows two lines, with Losartan Potassium consistently lower than Atenolol, indicating a 25% adjusted risk reduction (p=0.001). The x-axis represents study months (0 to 66), and the y-axis shows the percentage of patients.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

Figure 3 displays a forest plot illustrating primary endpoint events within demographic subgroups comparing losartan potassium and atenolol event rates for primary composite events and stroke (fatal/non-fatal). The chart shows hazard ratios with 95% confidence intervals for groups defined by age, gender, race, isolated systolic hypertension status, diabetes, and cardiovascular disease history, indicating relative risks between the two treatments.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo. The y-axis represents the percentage of patients with events, and the x-axis represents time in months. The graph shows a risk reduction of 16.1% with Losartan Potassium, with a statistical significance of p=0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium showing its molecular arrangement including functional groups and potassium counterion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.